Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin-dopamine activity modulator

European Neuropsychopharmacology

Volumn 25, Issue 3, 2015, Pages 356-364

  Yoshimi, Noriko ^a,b   Futamura, Takashi ^b   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

5 HT1A receptor; Antipsychotic drug; Brexpiprazole; Dizocilpine; Social recognition

Indexed keywords

BREXPIPRAZOLE; DIZOCILPINE; OLANZAPINE; RISPERIDONE; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG; WAY 100 635; AMINO ACID RECEPTOR BLOCKING AGENT; DIZOCILPINE MALEATE; DOPAMINE RECEPTOR STIMULATING AGENT; QUINOLONE DERIVATIVE; SEROTONIN RECEPTOR AFFECTING AGENT; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG ANTAGONISM; EXPERIMENTAL HYPERACTIVITY; EXPLORATORY BEHAVIOR; LOCOMOTION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOCIAL COGNITION; SOCIAL RECOGNITION DEFICIT; SOCIAL RECOGNITION TEST; SOCIALIZATION; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED; COGNITION DISORDERS; DOSE RESPONSE; DRUG EFFECTS; DRUG INTERACTION; RECOGNITION; SOCIAL BEHAVIOR;

ANALYSIS OF VARIANCE; ANIMALS; COGNITION DISORDERS; DIZOCILPINE MALEATE; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MICE; MICE, INBRED C57BL; QUINOLONES; RECOGNITION (PSYCHOLOGY); SEROTONIN AGENTS; SOCIAL BEHAVIOR; THIOPHENES;

EID: 84925944263     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.12.014     Document Type: Article

References (60)

1. Amann L.C., Gandal M.J., Halene T.B., Ehrlichman R.S., White S.L., McCarren H.S., Siegel S.J. Mouse behavioral endophenotypes for schizophrenia. Brain Res. Bull. 2010, 83:147-161.
2. Boix-Trelis N., Vale-Martinez A., Guillazo-Blanch G., Marti-Nicolovius M. Muscarinic cholinergic receptor blockade in the rat prelimbic cortex impairs the social transmission of food preference. Neurobiol. Learn. Mem. 2007, 87:659-668.
3. 1A agonist properties on PCP-induced social interaction deficits on the rat. Neuropharmacology 2005, 49:996-1006.
4. Dolen G., Darvishzadeh A., Huang K.W., Malenka R.C. Social reward requires coordinated activity of nucleus accumbens oxytocin and serotonin. Nature 2013, 501:179-184.
5. File S.E., Seth P. A review of 25 years of the social interaction test. Eur. J. Pharmacol. 2003, 463:35-53.
6. 2A receptors, and effects of their targeting on BTBR T+tf/J mouse social behavior. J. Neurochem. 2011, 116:291-303.
7. Gumuslu E., Mutlu O., Sunnetci D., Ulak G., Celikyurt I.K., Cine N., Akar F. The effects of tianeptine, olanzapine and fluoxetine on the cognitive behaviors of unpredictable chronic mild stress-exposed mice. Drug Res. 2013, 63:532-539.
8. 1A receptors. Eur. Neuropsychopharmacol. 2008, 18:448-454.
9. 1A antagonist, WAY 100,635, alleviates cognitive impairments induced dizocilpine (MK-801) in monkeys. Neuropharmacology 2000, 39:547-555.
10. Hashimoto K. The NMDA receptor hypofunction hypothesis for schizophrenia and glycine modulatory sites on the NMDA receptors as potential therapeutic drugs. Clin. Psychopharmacol. Neurosci. 2006, 4:3-10.
11. Hashimoto K. Targeting of NMDA receptors in new treatments for schizophrenia. Expert Opin. Ther. Targets 2014, 18:1049-1063.
12. Hashimoto K., Fujita Y., Shimizu E., Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. Eur. J. Pharmacol. 2005, 519:114-117.
13. Hashimoto K., Fujita Y., Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors. Neuropsychopharmacology 2007, 32:514-521.
14. Hashimoto K., Fujita Y., Horio M., Kunitachi S., Iyo M., Ferraris D., Tsukamoto T. Co-administration of a d-amino acid oxidase inhibitor potentiates the efficacy of d-serine in attenuating prepulse inhibition deficits after administration of dizocilpine. Biol. Psychiatry 2009, 65:1103-1106.
15. Hashimoto K., Malchow B., Falkai P., Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur. Arch. Psychiatry Clin. Neurosci. 2013, 263:367-377.
16. Henderson A.R. The impact of social cognition training on recovery from psychosis. Curr. Opin. Psychiatry 2013, 26:429-432.
17. Hikichi H., Kaku A., Karasawa J., Chaki S. Stimulation of metabotropic glutamate (mGlu) 2 receptor and blockade of mGlu1 receptor improve social memory impairment elicited by MK-801 in rats. J. Pharmacol. Sci. 2013, 122:10-16.
18. Horan W.P., Green M.F., DeGroot M., Fiske A., Hellemann G., Kee K., Kern R.S., Lee J., Sergi M.J., Subotnik K.L., Sugar C.A., Ventura J., Nuechterlein K.H. Social cognition in schizophrenia, Part 2: 12-month stability and prediction of functional outcome in first-episode patients. Schizophr. Bull. 2012, 38:865-872.
19. 1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats. Psychopharmacology 2012, 221:205-215.
20. 1A partial agonism. Behav. Brain Res. 2013, 247:158-164.
21. Karasawa J., Hashimoto K., Chaki S. d-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav. Brain Res. 2008, 186:78-83.
22. Krakowski M., Czobor P. Cholesterol and cognition in schizophrenia: a double-blind study of patients randomized to clozapine, olanzapine and haloperidol. Schizophr. Res. 2011, 130:27-33.
23. Lo P., Siu A.M. Social cognition and work performance of persons with schizophrenia in a Chinese population. Work 2015, (in press).
24. Maeda K., Sugino H., Akazawa H., Amada N., Shimada J., Futamura T., Yamashita H., Ito N., McQuade R.D., Mørk A., Pehrson A.L., Hentzer M., Nielsen V., Bundgaard C., Arnt J., Stensbøl T.B., Kikuchi T. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J. Pharmacol. Exp. Ther. 2014, 350:589-604.
25. Maeda K., Lerdrup L., Sugino H., Akazawa H., Amada N., McQuade R.D., Stensbøl T.B., Bundgaard C., Arnt J., Kikuchi T. Brexpiprazole II: antipsychotic-like profile and pro-cognitive effects of a novel serotonin-dopamine activity modulator. J. Pharmacol. Exp. Ther. 2014, 350:604-614.
26. Maehara S., Okuda S., Ohta H. Ameliorative effect of N-desmethylclozapine in animal models of social deficits and cognitive functions. Brain Res. Bull. 2011, 86:146-151.
27. Matsuo N., Tanda K., Nakanishi K., Yamasaki N., Toyama K., Takao K., Takeshima H., Miyakawa T. Comprehensive behavioral phenotyping of ryanodine receptor type 3 (RyR3) knockout mice: decreased social contact duration in two social interaction tests. Front. Behav. Neurosci. 2009, 3:3.
28. Meltzer H.Y., Horiguchi M., Massey B.W. The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology 2011, 213:289-305.
29. 1A receptors improve cognition in schizophrenia?. Behav. Brain Res. 2008, 195:98-102.
30. Millan M.J., Bales K.L. Towards improved animal models of evaluating social cognition and its disruption in schizophrenia: the CNTRICS initiative. Neurosci. Biobehav. Rev. 2013, 37:2166-2180.
31. 1A receptor partial agonist S15535 [4-(benzodioxan-5-yl)1-(indan-2-yl)piperazine] enhances cholinergic transmission and cognitive function in rodents: a combined neurochemical and behavioral analysis. J. Pharmacol. Exp. Ther. 2004, 311:190-203.
32. Moy S.S., Nadler J.J., Perez A., Barbaro R.P., Johns J.M., Magnuson T.R., Piven J., Crawley J.N. Sociability and preference for social novelty in five inbred strains: an approach to assess autistic-like behavior in mice. Genes Brain Behav. 2004, 3:287-302.
33. Moy S.S., Nadler J.J., Young N.B., Perez A., Holloway L.P., Barbaro R.P., Barbaro J.R., Wilson L.M., Threadgill D.W., Lauder J.M., Magnuson T.R., Crawley J.N. Mouse behavioral tasks relevant to autism: phenotypes of 10 inbred strains. Behav. Brain Res. 2007, 176:4-20.
34. Mutlu O., Celikyurt I.K., Ulak G., Tanyeri P., Akar F.Y., Erden F. Effects of olanzapine and clozapine on radial maze performance in naive and MK-801-treated mice. Arzneimittelforschung 2012, 62:4-8.
35. Mutlu O., Ulak G., Celikyurt I.K., Akar F.Y., Erden F. Effects of olanzapine, sertindole and clozapine on learning and memory in the Morris water maze test in naive and MK-801-treated mice. Pharmacol. Biochem. Behav. 2011, 98:398-404.
36. Nadler J.J., Moy S.S., Dold G., Trang D., Simmons N., Perez A., Young N.B., Barbaro R.P., Piven J., Magnuson T.R., Crawley J.N. Automated apparatus for quantitation of social approach behaviors in mice. Genes Brain Behav. 2004, 3:303-314.
37. 1A receptors. Psychopharmacology 2009, 202:315-328.
38. Nakatani J., Tamada K., Hatanaka F., Ise S., Ohta H., Inoue K., Tomonaga S., Watanabe Y., Chung Y.J., Banerjee R., Iwamoto K., Kato T., Okazawa M., Yamauchi K., Tanda K., Takao K., Miyakawa T., Bradley A., Takumi T. Abnormal behavior in a chromosome-engineered mouse model for human 15q11-13 duplication seen in autism. Cell 2009, 137:1235-1246.
39. Oh H.K., Park S.J., Bae S.G., Kim M.J., Jang J.H., Ahn Y.J., Woo H., Kwon G., Ryu J.H. Kami-ondam-tang, a traditional herbal prescription, attenuates the prepulse inhibition deficits and cognitive impairments induced by MK-801 in mice. J. Ethnopharmacol. 2013, 146:600-607.
40. Okamura N., Hashimoto K., Shimizu E., Kumakiri C., Komatsu N., Iyo M. Adenosine A1 receptor agonists block the neuropathological changes in rat retrosplenial cortex after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 2004, 29:544-550.
41. Rajagopal L., Massey B.W., Huang M., Oyamada Y., Meltzer H.Y. The novel object recognition test in rodents in relation to cognitive impairment in schizophrenia. Curr. Pharm. Des. 2014, 20:5104-5114.
42. Remberk B., Namyslowska I., Rybakowski F. Cognition and communication dysfunctions in early-onset schizophrenia: effect of risperidone. Prog. Neuropsychopharmacol. Biol. Psychiatry 2012, 39:348-354.
43. Riedel G., Kang S.H., Choi D.Y., Platt B. Scopolamine-induced deficits in social memory in mice: reversal by donepezil. Behav. Brain Res. 2009, 204:217-225.
44. Rogoz Z. Effect of combined treatment with mirtazapine and risperidone on the MK-801-induced changes in the object recognition test in mice. Pharmacol. Rep. 2013, 65:1401-1406.
45. Sergi M.J., Green M.F., Widmark C., Reist C., Erhart S., Braff D.L., Kee K.S., Marder S.R., Mintz J. Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am. J. Psychiatry 2007, 164:1585-1592.
46. 1A receptors. Behav. Brain Res. 2008, 191:26-31.
47. Sumiyoshi T., Higuchi Y., Uehara T. Neural basis for the ability of atypical antipsychotic drugs to improve cognition in schizophrenia. Front. Behav. Neurosci. 2013, 7:140.
48. Sumiyoshi T., Matsui M., Nohara S., Yamashita I., Kurachi M., Sumiyoshi C., Jayathilake K., Meltzer H.Y. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am. J. Psychiatry 2001, 158:1722-1725.
49. 1A agonist, on memory function in schizophrenia. Biol. Psychiatry 2001, 49:861-868.
50. 1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr. Res. 2007, 95:158-168.
51. Suzuki H., Gen K., Inoue Y. An unblinded comparison of the clinical and cognitive effects of switching from first-generation antipsychotics to aripiprazole, perospirone or olanzapine in patients with chronic schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:161-168.
52. Takatsu Y., Fujita Y., Tsukamoto T., Slusher B.S., Hashimoto K. Orally active glutamate carboxypeptidase II inhibitor 2-MPPA attenuates dizocilpine-induced prepulse inhibition deficits in mice. Brain Res. 2011, 1371:82-86.
53. Tandberg M., Ueland T., Sundet K., Haahr U., Joa I., Johannessen J.O., Larsen T.K., Opjordsmoen S., Rund B.R., Rossberg J.I., Simonsen E., Vaglum P., Melle I., Friis S., McGlashan T. Neurocognition and occupational functioning in patients with first-episode psychosis: a 2-year follow-up study. Psychiatry Res. 2011, 188:334-342.
54. Trapp W., Landgrebe M., Hoesl K., Lautenbacher S., Gallhofer B., Gunther W., Hajak G. Cognitive remediation improves cognition and good cognitive performance increases time to relapse-results of a 5 year catamnestic study in schizophrenia patients. BMC Psychiatry 2013, 13:184.
55. Tse S., Chan S., Ng K.L., Yatham L.N. Meta-analysis of predictors of favorable employment outcomes among individuals with bipolar disorder. Bipolar Disord. 2013, 16:217-229.
56. van der Kooij M.A., Sandi C. Social memories in rodents: methods, mechanisms and modulation by stress. Neurosci. Biobehav. Rev. 2012, 36:1763-1772.
57. 1 receptor-mediated neurotransmission. Neuropharmacology 2007, 53:379-389.
58. Wolff M.C., Leander J.D. Comparison of the effects of antipsychotics on a delayed radial maze task in the rat. Psychopharmacology 2003, 168:410-416.
59. 1A receptors. Pharmacol. Biochem. Behav. 2014, 124:245-249.
60. Zhang L., Shirayama Y., Iyo M., Hashimoto K. Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 2007, 32:2004-2010.